Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
Public ClinicalTrials.gov record NCT00111085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Study identification
- NCT ID
- NCT00111085
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Enrollment
- 413 participants
Conditions and interventions
Conditions
Interventions
- Clazosentan 1 mg/h Drug
- Clazosentan 5 mg/h Drug
- Clazosentan 15 mg/h Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2005
- Primary completion
- Mar 29, 2006
- Completion
- Mar 29, 2006
- Last update posted
- Jul 9, 2018
2005 – 2006
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Giuseppe Lanzino | Peoria | Illinois | — | — |
| Dr. Horner | Indianapolis | Indiana | — | — |
| Dr. Aldrich | Baltimore | Maryland | — | — |
| Dr. Ogilvy | Boston | Massachusetts | — | — |
| Dr. Zuccarello | Cincinnati | Ohio | — | — |
| Dr. Woo | Cleveland | Ohio | — | — |
| Dr. Rosenwasser | Philadelphia | Pennsylvania | — | — |
| Dr. Zager | Philadelphia | Pennsylvania | — | — |
| Dr. George A. Lopez | Houston | Texas | — | — |
| Dr. Bullock | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00111085 live on ClinicalTrials.gov.